Please assess the completion status of the following clinical trial:

Trial Title: Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with chronic PTSD for six months or longer.~* Have a CAPS score showing moderate to severe PTSD symptoms.~* At least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.~* Are at least 18 years old.~* Must be generally healthy.~* Are willing to refrain from taking any psychiatric medications during the study period.~* Willing to follow restrictions and guidelines concerning consumption of food, beverages or nicotine the night before and just prior to each MDMA session.~* Willing to remain overnight at the study site.~* Are willing to be driven home after experimental sessions either by a driver they arrange, a taxi, or study personnel.~* Are willing to be contacted via telephone by study personnel.~* If of child-bearing age, must have a negative pregnancy and agree to use an effective form of birth control.~* Must provide a personal contact who is willing to be reached in case of emergency.~* Agree to let the investigators know within 48 hours of any planned medical interventions.~* Are proficient in reading and speaking English.~* Agree to have all psychotherapy sessions recorded.~* Agree not to participate in any other interventional clinical trials during the course of the study.~Exclusion Criteria:~* Are pregnant or nursing, or if of child-bearing age and do not use an effective means of birth control.~* Weigh less than 48 kg.~* Are abusing illegal drugs.~* Are unable to give adequate informed consent.~* Upon review of past and current drugs/medication, must not be on or have taken a medication that is exclusionary.~* Upon review of medical or psychiatric history, must not have any current or past diagnosis that would be considered a risk to participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comparator-dose (40 mg) MDMA and Psychotherapy (Type: ACTIVE_COMPARATOR): Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
- Active Dose 2 (100 mg) MDMA and Psychotherapy (Type: EXPERIMENTAL): Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
- Active Dose 1 (125 mg) MDMA and Psychotherapy (Type: EXPERIMENTAL): Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).